The monthly frequently asked questions are compiled by DIG faculty, residents, and students. These summaries provide a concise overview of a current drug therapy topic.
Select year: Heading link
-
2024
- How do brexanolone and zuranolone compare in patients with postpartum depression?
- Is intravenous hydroxocobalamin an effective treatment for vasoplegia-associated shock?
- What information is available on vaccines for the prevention of RSV?
- What are the Available and Emerging Phosphodiesterase 4 Inhibitors for COPD Treatment?
- What are key pharmacologic recommendations in the management type 2 diabetes based on updated 2023 American Association of Clinical Endocrinologists (AACE) type 2 diabetes algorithm and 2024 American Diabetes Association (ADA) guidelines?
- What information is available on gene therapies for treatment of beta-thalassemia?
- Are there any guidelines supporting the use of metered dose inhalers (MDIs) versus nebulizers regarding infection transmission?
- What information is available on novel gene therapies for treatment of sickle cell disease?
- What is the role of colchicine in reducing the risk of cardiovascular events in adults?
- What information is available on the off-label use of gabapentin and topiramate for alcohol use disorder?
- What evidence supports the use of azithromycin for ruptured membranes in preterm prelabor?
- Does the available evidence support the use of anakinra in the management of constrictive pericarditis?
-
2023
- Is the use of piperacillin/tazobactam associated with risk of acute kidney injury?
- What are institutional perioperative practices for patients with alpha-gal allergy?
- What is the role of ketamine in the management of status epilepticus?
- What are the latest updates and recommendations on vaccination against COVID-19?
- Can thiazide diuretics cause increases in serum glucose?
- What efficacy data are available on the use of tirzepatide for obesity?
- Do data support the use of commercially available fecal microbiota transplantation products in managing recurrent Clostridioides difficile infection?
- Is there a risk of intraoperative aspiration with the use of GLP-1 receptor agonists?
- What data exists on the use of collagenase clostridium histolyticum (CCH) for the treatment of Peyronie’s disease?
- Does Granulocyte Colony Stimulating Factor Increase the Risk of Bleomycin Induced Lung Injury?
- A Summary of the 2023 American Geriatrics Society Updated Beers Criteria® for Potentially Inappropriate Medication Use in the Elderly
- What are current best practices on holding metformin prior to and post contrast administration?
- What literature supports the use of low-dose rifaximin in patients with hepatic encephalopathy?
- What data exists on the use of buprenorphine and buprenorphine-naloxone for the treatment of kratom withdrawal?
- Is there a preference between topical natamycin and topical voriconazole for first-line treatment of fungal keratitis?
- What evidence supports the use of ketamine in pain management of vaso-occlusive episodes in patients with sickle cell disease?
- What is the evidence for using greater than the FDA recommended dose of clobazam?
- Does the literature support the use of doxycycline for post-exposure prophylaxis against sexually transmitted infections?
- What evidence supports the use of neurokinin‐1 receptor antagonists for gastroparesis-related nausea and vomiting?
- What is the optimal duration of antibiotics for complicated UTI in a male patient?
- What is the update on long-term safety evidence with proton pump inhibitor use?
- Is weight loss sustained after discontinuation of glucagon-like peptide 1 receptor agonists for obesity?
- What information is available regarding the safety of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis?
- What evidence is available supporting the use of vitamin D in the treatment of asthma?
- What clinical evidence supports the use of lecanemab for Alzheimer disease?
- What considerations should pharmacists make in relation to teplizumab use in patients with type 1 diabetes mellitus?
- What data are available for sublingual dexmedetomidine in the treatment of acute agitation related to schizophrenia or bipolar disorder?
- Should allopurinol be given simultaneously with rasburicase for tumor lysis syndrome?
- Update: Can the intravenous formulation of vitamin K be administered orally?
- What literature is available on the use of enteral immunoglobulin for the treatment of norovirus enteritis?
- What data supports the use of alteplase 1 mg versus 2 mg for catheter occlusions?
- Does the available data support the use of liposomal bupivacaine for analgesia during vasectomy and vasectomy reversal procedures?
- Update: What evidence supports rectal indomethacin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis?
- What recent updates are available to guide decisions on use of immunosuppressant antirheumatic drugs perioperatively for orthopedic procedures?
- What data are available for systemic tenecteplase in submassive pulmonary embolism?
- What are current guideline recommendations for use of terlipressin in hepatorenal syndrome?
-
2022
- What literature exists on the practice of prescribing prophylactic antibiotics after pacemaker insertion or revision procedures?
- What evidence supports the recommendation for high-dose amoxicillin in children with acute otitis media?
- What is the role of tranexamic acid in patients with acute gastrointestinal bleeding?
- What is the evidence supporting the use of intravenous copper for copper deficiency?
- What evidence is available on use of IV magnesium sulfate for use in COPD exacerbation?
- What are the reasons to administer nebulized epinephrine?
- What data support initiation of antihypertensive therapy for mild chronic hypertension in pregnancy?
- What evidence supports current recommendations for monkeypox vaccination?
- What evidence is available for oral ketamine in treatment-resistant major depressive disorder?
- What evidence is there for the 5-day maximum with the use of ketorolac?
- What considerations should pharmacists prescribing nirmatrelvir-ritonavir for the treatment of COVID-19 in the outpatient population be aware of?
- What data are available to support switching between thrombopoietin receptor agonists in patients with immune thrombocytopenia?
- What are current recommendations for preventing surgical site infections in patients with trauma?
- What is the evidence for use, monitoring parameters, and treatment goals of agents for weight loss approved in the last 10 years?
- Is there any literature to support the use of a proton pump inhibitor (PPI) plus a histamine-2-receptor antagonist (H2RA) for gastroesophageal reflux disease (GERD)?
- What is the role of oral ketamine in pain management?
- What is the evidence supporting combination therapy with amphotericin B and either azole antifungals or echinocandins for the treatment of mucormycosis?
- What evidence supports the initiation of sodium-glucose cotransporter 2 inhibitors during acute decompensated heart failure?
- Are direct oral anticoagulants safe and effective for the treatment of adults with cerebral venous thrombosis (CVT)?
- What evidence supports the use of fibrinogen concentrate to minimize the need for blood transfusions?
- Update: what evidence supports intravenous tenecteplase for the treatment of acute ischemic stroke?
- What is the strength of evidence available on the risk of GI bleeding with direct oral anticoagulants?
- Do data support the use of oral vancomycin prophylaxis for primary prevention of Clostridium difficile infection CDI in high-risk patients?
- What new evidence is available to support the use of direct oral anticoagulants (DOACs) in pediatric patients for venous thromboembolism (VTE) treatment and prevention?
- What is the place in therapy for empagliflozin for heart failure?
- What drug therapy is recommended for management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy?
- What is the optimal sequencing for first-line treatment of BRAF-mutated metastatic melanoma?
- What is the recommended duration of anticoagulant therapy for pediatric patients with venous thromboembolism (VTE)?
- Update: What are the 2021 pharmacotherapy updates to the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock?
- Update: Should tranexamic acid be added to the standard of care in treating postpartum hemorrhage?
- What are the updated recommendations for naming monoclonal antibodies?
- Update: Is oral vancomycin prophylaxis (OVP) beneficial for secondary prevention of Clostridioides difficile infection (CDI)?
- What is the optimal dosing of intracavernous phenylephrine for acute ischemic priapism?
- What are the updated treatment recommendations for chlamydia and gonococcal infections?
- What are the new recommendations regarding estimation of glomerular filtration rate without the variable for race, and what effects might this have on drug dosing?
- What evidence supports intravenous tenecteplase for the treatment of acute ischemic stroke?
-
2021
- What data supported the removal of the pregnancy contraindication from statin labeling?
- What literature is available on selective serotonin reuptake inhibitor use for post-stroke recovery?
- What evidence is available regarding the efficacy of COVID-19 vaccine booster shots in adults?
- What are the 2021 guideline updates on the management of Clostridioides difficile infection (CDI) in adults?
- Are there data available to support use of fixed-dose cisatracurium for acute respiratory distress syndrome (ARDS)?
- What are the implications of the COVID-19 pandemic on respiratory syncytial virus (RSV) infection prophylaxis with palivizumab?
- What data support a thrice-weekly regimen of ertapenem therapy in patients with end-stage renal disease on intermittent hemodialysis?
- What literature is available describing the occurrence of bradycardia with remdesivir?
- What is the clinical evidence supporting, and controversy surrounding, the use of aducanumab (Aduhelm TM) for Alzheimer disease?
- What evidence is available for use of the newest mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease?
- Are there any data to support administration of a second course of intravenous immunoglobulin in patients with Guillain-Barré syndrome unresponsive to a first course?
- 2021 Update: What are considerations for determining whether a drug may be administered via a midline catheter?
- What are current recommendations for filtering parenteral nutrition (PN) admixtures?
- What evidence is available regarding thrombosis and thrombocytopenia associated with adenoviral vector-based COVID-19 vaccines?
- What information is available on the management of potential drug interactions with the COVID-19 vaccine?
- What recommendations are available regarding the timing of administration of the COVID-19 vaccine with regard to immunosuppressant medications?
- Update: What is the evidence for use of high-dose vitamin C in critically ill patients with sepsis?
- What evidence supports the addition of metronidazole to the standard regimen of ceftriaxone and doxycycline for the treatment of pelvic inflammatory disease?
- What data are available to support extended-release bupivacaine/meloxicam for post surgical analgesia?
- Why has bacitracin for injection been withdrawn, and are alternative irrigation solutions recommended to prevent pocket infection during implantation of cardiovascular implantable electronic devices?
- In patients with severe COVID-19, are there data to support the use of dexamethasone or methylprednisolone doses greater than dexamethasone 6 mg daily or equivalent?
- What drugs are likely to interfere with urine drug screens?
- What evidence supports new disease-modifying drug therapies in sickle cell disease?
- Update: What is the optimal dosing of 4-factor prothrombin complex concentrate in patients with warfarin-associated bleeding?
- What is the evidence on the use of high-dose nitroglycerin for SCAPE?
- What evidence is available regarding the off-label use of spinal mepivacaine versus bupivacaine for total hip and total knee arthroplasty?
- What evidence is available for intranasal esketamine as a treatment for acute depression/suicidal ideation in the emergency department?
- What technology is used in vaccines against coronavirus disease 2019?
- What should I, as a pharmacist, know about long-COVID?
- What is the place in therapy for monoclonal antibodies in outpatients with COVID-19?
- What are current recommendations for treatment of drug extravasation?
- What evidence supports the use of Clorpactin (sodium oxychlorosene) for the treatment of urinary tract infections?
- Update: What is the evidence for the use of albumin for treatment of intradialytic hypotension?
- Update: What do pharmacists need to know about convalescent plasma for COVID-19?
- Should appetite stimulants be used in pediatric patients with cancer?
- What vaccines should be administered to adult patients who have asplenia or hyposplenia?
- What is the risk of QT prolongation with droperidol?
-
2020
- What outcomes data are available for cefiderocol in the treatment of serious, resistant infections?
- What evidence supports the use of oliceridine for severe pain?
- Is there information on intrawound/topical vancomycin powder in craniotomy?
- Is oral vancomycin prophylaxis (OVP) beneficial for secondary prevention of Clostridioides difficile infection (CDI)?
- What are the pharmacologic options for managing pica in pregnant women?
- Update: What evidence is available on the off-label use of dexmedetomidine for alcohol withdrawal syndrome?
- Update: What evidence supports the use of direct-acting oral anticoagulants in patients with cancer-related VTE?
- How should unfractionated heparin be monitored in patients transitioning from oral factor Xa inhibitors?
- What is the role of dapagliflozin for treatment of heart failure?
- What data supports imipenem-cilastatin/relebactam’s new indication for bacterial pneumonia?
- What information is available regarding screening and treating asymptomatic bacteriuria prior to select nonurologic surgeries?
- Update: What data support the use of andexanet alfa (ANDEXXA) for the reversal of factor Xa inhibitors?
- What do pharmacists need to know about the Emergency Use Authorization for convalescent plasma for COVID-19?
- What efficacy supports the use of liposomal bupivacaine for post-Cesarean pain control?
- Are there data to support the use of IV meloxicam for perioperative pain control in orthopedic surgery patients?
- What evidence supports transitioning from dexmedetomidine to clonidine for sedation management?
- What recommendations are available for laboratory monitoring of direct oral anticoagulants (DOAC)?
- What drugs should be avoided in myasthenia gravis?
- What is the controversy surrounding testosterone replacement therapy?
- What information is available regarding use of anticoagulation in the management of COVID-19?
- What information is available regarding the risks of ACE inhibitor or ARB use during the COVID-19 pandemic?
- What data are there to support use of tocilizumab in critically ill patients with COVID-19?
- What evidence supports the use of colchicine for secondary prevention after an acute myocardial infarction?
- What information is available regarding the use of chloroquine or hydroxychloroquine for treatment of COVID-19?
- Are there data to support the use of oral albuterol for acute respiratory symptoms when inhalation treatment is unavailable or inappropriate?
- What evidence supports the use of tranexamic acid in patients with traumatic brain injury?
- What is the evidence available for treatment of COVID-19 with lopinavir/ritonavir or remdesivir?
- What should I, as a pharmacist, know about COVID-19?
- What literature is available for the use of inhaled tranexamic acid in hemoptysis?
- Is there literature describing the efficacy or safety of inhaled vancomycin to treat MRSA ventilator-associated tracheobronchitis?
- What is the new recommendation for 13-valent pneumococcal vaccine in elderly adults?
- Is melatonin an effective treatment option for the prevention of hospital-induced delirium?
- What evidence supports the use of oral tranexamic acid for major orthopedic surgery?
- What evidence is available comparing pegfilgrastim administration on day of versus day after chemotherapy?
- What data are available to support the use of bisphosphonates in calciphylaxis?
- What information is available on use of water-soluble contrast agents for uncomplicated adhesive small bowel obstruction?
- What is the recommended frequency and duration of electrocardiogram monitoring in patients receiving intravenous haloperidol?
-
2019
- What recent changes may influence pharmacotherapy of community-acquired pneumonia?
- What are the most recent updates from the Advisory Committee on Immunizations Practices regarding HPV vaccination?
- What guidance is available for tapering long-term opioid analgesics?
- Update: What information has been yielded from the cardiovascular safety studies on new anti-hyperglycemic agents?
- What criteria exist to suggest use of denosumab for the treatment of hypercalcemia of malignancy over other calcium reducing options?
- What is the pharmaceutical contaminant N-nitrosodimethylamine (NDMA) and what risk does it pose to humans?
- What is the clinical relevance of the clopidogrel/proton pump inhibitor (PPI) interaction?
- What is the comparative diagnostic value of the novel somatostatin analog radiotracers for SSRT PET?
- What data are available regarding short versus long duration of antibiotic treatment for uncomplicated Enterobacteriaceae bacteremia?
- What evidence supports the use of oral factor Xa inhibitors for VTE prevention in patients with cancer?
- Do psychostimulants cause tics?
- Is there evidence to support the use of echinocandins for urinary tract infection?
- What are alternatives to erythromycin ophthalmic ointment for prophylaxis of gonococcal ophthalmia neonatorum?
- Update: Does extended infusion piperacillin-tazobactam (Zosyn) improve clinical outcomes?
- Is there literature to support the combined use of lactulose and rifaximin for the treatment of acute overt hepatic encephalopathy?
- What is the evidence for rectal indomethacin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis?
- What is the optimal duration of antimicrobial surgical site infection prophylaxis in cardiac surgery?
- What evidence is available for the use of capsaicin in cannabinoid hyperemesis syndrome?
- What is the evidence for using haloperidol for migraines in the emergency department?
- Update: What is the safety information available on the use of DOACs in patients with renal impairment?
- Is intravenous ketamine effective for treatment of headache disorders in the emergency department?
- Does elevated INR in hospitalized patients with chronic liver disease suggest that anticoagulation is not necessary?
- Is ticagrelor the optimal antiplatelet for patients with peripheral artery disease?
- Is there a role for newer cation exchange resins (ie, patiromer and sodium zirconium cyclosilicate) in the emergency management of hyperkalemia?
- Update: What data are available to direct dosing of intravenous immunoglobulin G based on total versus ideal or adjusted body weight?
- What evidence exists to support the use of nebulized sodium bicarbonate as a mucolytic in hospitalized patients?
- What is the available literature regarding use of KCentra® (Four Factor Prothrombin Complex Concentrate) (4F-PCC) for the treatment of coagulopathies and acute hemorrhage in patients with liver disease who are not receiving concomitant anticoagulation therapy?
- What data exist for the use of tolvaptan beyond 30 days in the setting of hyponatremia?
- What are anesthesia safety considerations related to patients taking cannabis?
- Can alteplase be used to clear occluded chest tubes?
- What is the latest evidence on alternatives to magnesium sulfate in patients with preeclampsia and eclampsia?
- What are the Infectious Diseases Society of America recommendations for the diagnosis and management of seasonal influenza?
- What clinical data are available comparing nicardipine to clevidipine in acute ischemic stroke?
- What evidence is available to support the use of N-acetylcysteine for impulse control disorders?
- What evidence supports the use of direct-acting oral anticoagulants in patients with cancer-related VTE?
-
2018
- Does administration of sodium bicarbonate to patients with severe metabolic acidosis yield a mortality benefit?
- What data support use of topical tranexamic acid for epistaxis in adults?
- What is the evidence for online vancomycin dose calculators?
- What are important considerations for using cannabidiol for the treatment of pediatric seizures?
- What are the 2018 SCCM guideline recommendations for pain, agitation/sedation, delirium, immobility, and sleep disruption (PADIS)?
- Is intravenous lidocaine effective for renal colic in patients with urolithiasis?
- What data are available to support administration of high-dose (>200 mg) iron sucrose in patients with non-dialysis-dependent chronic kidney disease?
- What is the appropriate management of acute pain in a patient with opioid use disorder?
- Probiotics and Clostridium difficile infections: What do we know now?
- What is the emerging pathogen Candida auris and what should pharmacists know about it?
- What role does intravenous magnesium play in the management of migraines?
- What clinical data are available comparing meropenem 500 mg every 6 hours to meropenem 1000 mg every 8 hours?
- What data support the use of andexanet alfa (ANDEXXA) for the reversal of factor Xa inhibitors?
- What new data are available linking an increased infection risk with chronic opioid therapy?
- Can intraoperative methadone reduce postoperative opioid requirements?
- What is the efficacy and safety of IV acetaminophen when compared to oral acetaminophen?
- What is the clinical efficacy of fish-oil containing lipid emulsion products compared to soybean oil-based lipid emulsion products for parenteral nutrition?
- What is the evidence on the use of valbenazine (Ingrezza) for tardive dyskinesia?
- What is the current evidence on using aromatherapy for treating postoperative nausea and/or vomiting?
- What data are available to support etelcalcetide in hemodialysis patients with secondary hyperparathyroidism?
- What guideline recommendations are available regarding perioperative multimodal analgesia (MMA)?
- Update: What are aminophylline alternatives for the reversal of adenosine agonists used in pharmacologic stress testing?
- In critically ill patients, do balanced solutions improve renal outcomes and decrease mortality when compared to normal saline?
- What evidence is available for enoxaparin dosing for VTE prophylaxis in patients undergoing bariatric surgery?
- Is there a potential for misuse and abuse with gabapentin (Neurontin®) and pregabalin (Lyrica®)?
- What is the evidence behind the recent approval of the Shingrix vaccine?
- What is the appropriate management of tetanus exposure?
- Is one type of influenza vaccine more effective than another?
- What is the role of Giapreza (angiotensin II) in shock?
- What data are available for intravenous immune globulin (IVIG) in Clostridium difficile infection?
- Are there data to support an increased risk of heart failure exacerbation/decompensation with pregabalin use?
- What does the PRESERVE trial tell us about the prevention of contrast-induced acute kidney injury?
- What data supports the efficacy and safety of meropenem-vaborbactam?
- What is alpha-gal allergy and how does it impact medication therapy?
- What is the evidence for the use of high-dose intravenous vitamin C for the treatment of cancer?
- What are considerations for determining whether a drug may be administered via a midline catheter?
-
2017
- What information has been yielded from the cardiovascular safety studies on new anti-hyperglycemic agents?
- Should tranexamic acid be added to the standard of care in treating postpartum hemorrhage?
- What evidence is available on adult dosing of vancomycin in obesity?
- What is the evidence for decolonization with an alcohol-based nasal antiseptic?
- What evidence supports combining insulin and other antidiabetic medications in adults with type 1 diabetes?
- What is the appropriate management of rabies exposure?
- What is the appropriate management of hemorrhagic cystitis?
- How can sodium acetate be used as a substitute for sodium bicarbonate, and what other strategies are recommended for sodium bicarbonate shortage management?
- What are cardioplegia solutions?
- How is acute kidney injury defined in pediatric patients?
- What data are available on use of N-acetylcysteine in the management of non-acetaminophen drug-induced liver injury?
- What are the new data regarding risk of sudden death in heart failure?
- What is the role of minocycline in the treatment of multidrug resistant organisms?
- What evidence supports the use of coenzyme Q10 supplementation to prevent or treat statin-associated myopathy?
- What evidence is available on the use of intravenous sildenafil for pulmonary arterial hypertension?
- Is pregabalin effective for the treatment of sciatica pain?
- What evidence is available to support the use of anti-factor Xa levels instead of activated partial thromboplastin time for monitoring of intravenous unfractionated heparin therapy in adults?
- Are there any new safety concerns with antibiotics in pregnancy?
- Can olanzapine be administered intravenously for the management of acute agitation?
- What evidence supports the use of intravenous sub-dissociative-dose ketamine for pain in the emergency department?
- What is the available evidence for the use of alteplase for occlusion of peritoneal dialysis catheters?
- What is the role of bezlotoxumab in treating Clostridium difficile infections?
- What is the evidence for use of high-dose vitamin C in critically ill patients?
- How does brivaracetam compare to other antiepileptic agents in treating refractory partial onset seizures (POS)?
- What evidence is available for the use of aprepitant (Emend) compared to other antiemetics for the prevention of postoperative nausea and vomiting?
- What handling precautions should be taken when preparing monoclonal antibody drugs?
- What are the American Heart Association’s recommendations for managing NOACs in acute care and peri-procedurally?
- What evidence evaluates the use of procalcitonin to guide antibiotic duration in patients with hospital-acquired or ventilator-associated pneumonia?
- What is the usual clinical presentation, diagnosis, and management of norovirus infection?
- Which is the best method for administration of pancreatic enzyme replacement products by enteral feeding tube?
- Can direct oral anticoagulants be prescribed to patients taking carbamazepine?
- Are there data to support the treatment of Pseudomonas infections with cefepime 1 gram every 6 hours vs. 2 grams every 8 hours?
- What are the treatment options for post-operative shivering?
- What are the updated recommendations for the role of PCSK9 inhibitors in the management of hypercholesterolemia?
- What literature supports the use of liposomal bupivacaine in transversus abdominis plane nerve blocks?
- What evidence is available for using direct oral anticoagulants in HIT?
-
2016
- What is the optimal dosing of 4-factor prothrombin complex concentrate in patients with warfarin-associated bleeding?
- Is there updated information on the off-label use of dexmedetomidine (Precedex®) for alcohol withdrawal syndrome?
- What is the available evidence for the use of sodium thiosulfate for non-uremic calciphylaxis?
- What drugs can be used to manage floppy iris syndrome during cataract surgery?
- What is the latest information on gadolinium-based contrast agents and brain deposits?
- Is there literature to support the adjunct use of simethicone prior to colonoscopy to improve visualization?
- What are the data on efficacy and safety of using injectable tobramycin for inhalation via nebulization?
- What are the comparative clinical data for albuterol versus levalbuterol?
- What evidence supports the efficacy of ranolazine (Ranexa®) for the treatment of atrial fibrillation?
- Dexrazoxane and the risk secondary cancer in pediatric patients: Can this controversy be laid to rest?
- What are alternatives to sublingually administered ophthalmic atropine for treatment of noisy breathing in terminally ill patients?
- How should medications be appropriately managed following bariatric surgery?
- What evidence supports the use of antibiotic-loaded bone cement to prevent infection in primary hip and knee arthroplasty?
- What does the American Psychiatric Association recommend regarding the use of antipsychotics in patients with dementia?
- Can a simplified 2-bag acetylcysteine approach improve tolerability in acetaminophen overdoses?
- What evidence is available for the use of fluorescein for gastrointestinal and genitourinary procedures?
- What is the evidence to support the new 2016 heart failure update and place in therapy of the new heart failure agents?
- What is the comparative evidence on use of IV acetaminophen versus oral acetaminophen?
- What evidence is available for efficacy and stability of high dose mitomycin C concentrations?
- What evidence supports or refutes the use of medical grade honey for wound healing?
- What are the new 2016 ACC/AHA guideline recommendations for dual antiplatelet therapy?
- What are the key changes to drug therapy recommendations in the 2016 AACE type 2 diabetes algorithm?
- What are the clinical implications of the 2016 American Epilepsy Society (AES) guidelines for status epilepticus?
- What is the clinical evidence for the use of sugammadex (Bridion®)?
- What are the 2016 guideline recommendations for the management of postoperative pain?
- What is the most recent evidence for using probiotics in patients with Clostridium difficile?
- Does adjunctive corticosteroid therapy improve outcomes in patients with community-acquired pneumonia?
- What data support selexipag and initial ambrisentan/tadalafil therapy for pulmonary arterial hypertension?
- What information is available on Zika virus infection?
- What are the major drug-related changes to the 2016 update of the CHEST Guideline for Antithrombotic Therapy for VTE Disease?
- Do the insulin glargine products Basaglar and Lantus have similar safety and efficacy profiles?
- Should blood pressure goals be lowered based on recent evidence?
- Are proton pump inhibitors (PPIs) associated with negative outcomes in patients with cirrhosis?
- What data are available comparing liposomal bupivacaine to other agents?
- Can estimated patient weight be safely used for dosing of alteplase for acute ischemic stroke?
- What are the key features of the new rheumatoid arthritis guidelines?
-
2015
- What is known about idarucizumab for dabigatran reversal?
- What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention?
- What is the role of topical tranexamic acid to prevent postsurgical bleeding from major cardiovascular and orthopedic procedures?
- What are the key features of the most recent guidelines for the management of patients with atrial fibrillation?
- What recent evidence describes the comparative safety and efficacy of bivalirudin and heparins in patients undergoing percutaneous coronary intervention?
- Can the intravenous formulation of vitamin K be administered orally?
- Can angiotensin receptor blockers (ARBs) be administered to patients who develop angioedema on angiotensin-converting enzyme inhibitor (ACEI) therapy?
- What are the data to support the use of ethanol lock therapy to decrease catheter-related infections in pediatric patients?
- What is the cross-reactivity of penicillins and carbapenems in a patient with a penicillin allergy?
- Can intermittent proton pump inhibitor dosing be used in acute upper gastrointestinal bleeding?
- What data support the safety and efficacy of the intravenous P2Y12 inhibitor cangrelor?
- Is the recently updated cholesterol guideline cost-effective and better at identifying at-risk patients than the previous ATP III guideline?
- How will fusion technology for factor concentrates change prophylaxis strategies in the management of hemophilia A and B?
- How should allergic reactions to local anesthetics be managed?
- What is the efficacy and safety evidence for Zarxio (filgrastim-sndz), the first biosimilar approved in the United States?
- What are the new recommendations for 13-valent pneumococcal conjugate vaccine (PCV13) in older adults?
- What is the safety information available on the use of NOACs in patients with renal impairment?
- How should patients receiving new oral anticoagulants be managed prior to planned surgical procedures?
- What is the evidence to support twice-daily dosing of insulin glargine?
- What is the rationale and significance of the FDA’s new guidance for abuse-deterrent opioids?
- What should healthcare providers know about PCSK9 inhibitors, the new class of cholesterol-lowering medications?
- What evidence supports the efficacy of the new antibiotic, ceftazidime/avibactam (Avycaz)?
- What should healthcare providers know about the recent measles outbreak in the United States?
- What are the current recommendations for managing patients initiating non-VKA oral anticoagulants (NOACs) after receiving thrombolytic therapies for pulmonary embolism?
- What drugs should be avoided in myasthenia gravis?
- Is normal saline or heparin preferred as a catheter flush solution?
- Should warfarin be resumed after gastrointestinal bleeding, and if so – when?
- What are the new guidelines for the pharmacological management of obesity?
- What information is available on the use of peramivir for treatment of influenza?
- What data supports the use of new oral anticoagulants in special populations (hepatic impairment, obesity, pregnancy, lactation, and pediatrics)?
- What are the new recommendations for direct-acting antivirals for treatment of hepatitis C virus?
- What is the Evidence for Use of Inhaled Epoprostenol?
- What vaccines should be administered to adult, splenectomized, patients?
- What is the Evidence for Use of Bronchodilators in Bronchiolitis?
- What are Current Recommendations for Treatment of Drug Extravasation?
- Is Vancomycin Therapy with Targeted Troughs Between 15 and 20 mg/L Associated with an Increased Risk of Nephrotoxicity?
-
2014
- What evidence supports the efficacy of dalbavancin for the treatment of ABSSSIs?
- What treatment options are available for the reversal of novel oral anticoagulants?
- What is the evidence for the safety and efficacy of tedizolid for the treatment of ABSSSIs?
- What is the status of biosimilars in the United States?
- Preexposure prophylaxis for HIV prevention: What are the new guidelines?
- How should acute pain be managed in patients taking Suboxone?
- What is the new evidence behind the effectiveness of β-blocker therapy for outcomes post-myocardial infarction?
- What are the findings of the HEAT-PPCI trial?
- What is the role of thrombolysis in submassive pulmonary embolism?
- What evidence supports the use of extended or continuous infusions for carbapenem administration?
- What evidence describes the effect of inhaled morphine for dyspnea or pain?
- What is the new guidance regarding palivizumab (Synagis®) administration for respiratory syncytial virus?
- What are the proposals of the new USP chapter, ‘ Hazardous Drugs – Handling in Healthcare Settings ? ‘
- How should beyond-use-dates for compounded preparations be determined?
- Is intravenous ketamine useful for the treatment of major depressive disorder?
- Can patients with recurrent C difficile infection be treated with a prepared fecal microbiota transplant product?
- What data are available comparing liposomal bupivacaine to other agents?
- What is the Target: Stroke initiative and its effect on stroke outcomes?
- What are the recommendations regarding blood pressure management in patients with an acute ischemic stroke?
- What evidence supports the efficacy of the new oral factor Xa inhibitor, edoxaban?
- Does testosterone increase the risk of a cardiovascular event?
- What is the effective dose and duration of oral ribavirin for immunocompromised adult patients with RSV infection?
- Is there any information regarding reducing the adverse effects from acetylcysteine in acetaminophen overdose?
- What are the current guidelines on treatment of hyponatremia with vasopressin antagonists?
- Is there a benefit to using colloid solutions versus crystalloid solutions as fluid resuscitation for patients with hypovolemic shock?
- What drug products may be used in patients with anemia or hemorrhage who are Jehovah’s Witnesses?
- What data are available to direct the dosing weight used for daptomycin in obesity?
- Are there benefits to using genotype-guided warfarin dosing for INR control?
- Does perioperative use of selective serotonin reuptake inhibitors increase the risk of adverse outcomes?
- What is the evidence for the use of albumin for treatment of intradialytic hypotension?
- What are the key features of the new hypertension treatment guidelines?
- How do the novel oral anticoagulants compare to low-molecular-weight heparin for prevention of venous thromboembolism in patients undergoing total hip or knee replacements?
- Is there evidence to support the use of lidocaine to reduce pain associated with potassium infusions?
- What is the latest evidence associating statin use with myopathy?
- What are current best practices for prevention of central-line associated bloodstream infections?
- What are the key features of the new cholesterol treatment guidelines?
-
2013
- What is the comparative efficacy of brand Plavix and generic clopidogrel bisulfate?
- Are there data to support the use of medroxyprogesterone for postpartum hemorrhage?
- Can dexmedetomidine be used off-label in the management of alcohol withdrawal syndromes?
- What are the most recent recommendations for occupational postexposure prophylaxis(PEP)?
- What are the safety concerns with electronic cigarettes (“e-cigarettes”),and do they have a role in smoking cessation?
- What data are available to direct dosing of intravenous immunoglobulin G based on total versus ideal or adjusted body weight?
- Should perioperative beta blockers be used to prevent cardiac complications in non-cardiac surgeries?
- What comparative data are available for biologics in the setting of rheumatoidarthritis?
- Is it necessary to bridge with heparin in high-risk patients before pacemaker or defibrillator surgery?
- What is the recommended treatment for shivering related to therapeutic hypothermia?
- What data support the addition of metronidazole to empiric antibiotic regimens in the treatment of aspiration pneumonia?
- Are most classically described side effects of beta-blocker therapy in heart failure actually due to the medication?
- Does the development of direct acting antivirals for hepatitis C virus mark the end of an era for treatment with interferon?
- What evidence led to the boxed warning on hydroxyethyl starch solutions?
- What literature is available supporting short-term use of systemic antibiotics for prevention of ventilator-associated pneumonia?
- Does azithromycin increase the risk of cardiovascular death?
- What safety risks prompted the labeling change that recommend against epidural administration of triamcinolone acetonide (Kenalog)?
- What is the efficacy of prothrombin complex concentrates in the management of vitamin K antagonist-related major bleeding?
- What are the differences and similarities between the Medical Letter antimicrobial prophylaxis guidelines and the guidelines from ASHP/IDSA/SIS/SHEA?
- Should zolpidem use be minimized due to increased risk of falls in hospitalized patients?
- What are the updated guideline recommendations for management of opportunistic infections in patients with HIV?
- What available alternatives are there to papaverine for the prevention and management of vasospasm during cardiac procedures?
- What are the alternatives to alteplase for catheter clearance?
- How do methylene blue and isosulfan blue compare for use in sentinel lymph node biopsy?
- What are the differences between the recent ASCO guideline on antibiotic use for neutropenia and those from the Infectious Diseases Society of America?
- What data are available to guide appropriate off-label use of the peripheral mu-opioid receptor antagonists, methylnaltrexone and alvimopan?
- What are the risk factors associated with supratherapeutic dosing of acetaminophen in hospitalized patients?
- What are aminophylline alternatives for the reversal of adenosine agonists used in pharmacologic stress testing?
- What are the new recommendations for frequency of platelet monitoring in patients with heparin-induced thrombocytopenia?
- What are the new guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients?
- What are the updated guideline recommendations for management of pain, agitation, and delirium in critically ill adult patients?
- Drug-induced QT prolongation (Part 2): a focus on select medications
- What are the new clinical guidelines for the management of gastroparesis?
- Does parenteral iron administration increase the risk of infection?
- Drug-induced QT prolongation (Part 1): presentation, risks, and management
- Should tamoxifen therapy be extended up to 10 years in women with early breast cancer?